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Abstract 
Nitroxyl (HNO) is currently a vasorelaxant of high interest, but as yet its mechanisms of 
action have not been fully elucidated. It is thought that HNO acts on KV channels to mediate 
vasorelaxation, and this has been shown in previous studies (Irvine et al, 2003; Favarolo & 
Kemp-Harper, 2009; Yuill et al, 2011). It has also been shown that high levels of glucose 
inhibit KV channels (Rainbow et al, 2006) so would inhibit HNO mediated relaxation. This 
study could provide further evidence of KV involvement of HNO mediated vasodilation. 
This study uses a temperature controlled organ bath with aortic ring preparations obtained 
from male Wistar rats, which were killed using approved schedule 1 methods. The section of 
aorta was connected to an isometric transducer linked to LabChart software. This was used 
to measure changes in tension in response to the addition of increasing concentrations of 
sodium nitroprusside (SNP) and Angeli’s salt. These tension changes were quantified and 
converted to percentage of total relaxation, and presented graphically. 
The results show that greater relaxation is achieved with Angeli’s salt at high concentrations 
(>1μM) under normal levels of glucose then under elevated levels of glucose, in both 
experiments with and without the HNO scavenger L-Cysteine. The lowest level of relaxation 
achieved was with Angeli’s salt with hydroxocobalamin (HxC) with high levels of glucose 
present. 
These results would appear to show that high glucose has the ability to inhibit HNO 
mediated relaxation. This would further indicate that KV channels are involved in 
vasorelaxation by HNO, which concurs with data from earlier studies (Irvine et al, 2003; 
Favarolo & Kemp-Harper, 2009; Yuill et al, 2011; Rainbow et al, 2006). 
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Introduction 
Nitroxyl (HNO) is a relatively recently discovered vasodilator, with largely speculated 
mechanisms of action, although it is thought to play a major role in endothelium 
dependant vasodilation, similar to nitric oxide (NO) (Yuill, 2011). There is some 
speculation that HNO may also be generated endogenously to perform this role, 
however there are insufficient detection methods, meaning that this cannot be 
conclusively proved (Paolocci et al, 2007; Irvine et al, 2008). Methods of 
endogenous generation of HNO that have been postulated include the oxidation of 
hydroxylamine (Donzelli et al, 2008) or the oxidation of N-hydroxy-L-arginine (Fukuto 
et al, 1992). Wong et al in 1998 hypothesised that the endogenous generation of 
HNO may be due to the reaction of S-nitrosothiols with thiols. In addition, further 
reaction of S-nitrosothiols with HNO can produce NO, a known vasorelaxant (Wong 
et al, 1998). 
The vasodilation elicited by HNO is thought to be due to its interaction with soluble 
guanylate cyclase (sGC), which causes conversion of GTP to cyclic GMP (cGMP), 
resulting in cGMP mediated relaxation of the smooth muscle (Irvine et al, 2008). This 
mechanism has been shown in rat models with the inhibition of sGC by ODQ, which 
caused reduced vasodilation due to reduced levels of cGMP (Ellis et al, 2000; Irvine 
et al, 2007; Wanstall et al, 2001). 
One explanation for the vasodilatory effects of HNO is the oxidation of HNO to NO 
by superoxide dismutase (SOD) (Liochev & Fridovich, 2002). However, uncertainty 
remains as to whether SOD directly oxidises HNO or whether its actions are due to 
the scavenging of superoxide (Zeller et al, 2009). One study, by Zeller et al (2009), 
concluded that the activation of sGC by HNO and the resulting vasodilation was 
solely due to the oxidation of HNO to NO.  
However, there is also an opposing hypothesis that HNO elicits its actions in an NO 
independent manner. Several studies have shown that vasodilation by the actions of 
HNO was blocked by ODQ, a sGC inhibitor, but no blockade was achieved with the 
NO scavenger carboxy-PTIO, meaning there was no involvement of NO (Costa et al, 
2001; Irvine et al, 2003; Irvine et al, 2007; Li et al, 1999; Wanstall et al, 2001). 
Certain sGC independent pathways have been described for the actions of HNO. A 
study by Yuill et al in 2011 showed that high conductance calcium activated 
potassium (BKCa) channels were active during vasodilation with HNO, tested using 
specific channel inhibitors. However, there was also inhibition of vasodilation by 
ODQ suggesting that sGC may still be involved in this pathway. This study also ruled 
out oxidation of HNO to NO by using NO scavengers. 
A 2003 study by Irvine et al showed that voltage gated potassium (KV) channels, 
were activated by HNO. This study concluded that KV channels were the only 
potassium channels involved, as inhibitors if this channel type blocked relaxation, 
and inhibitors of other potassium channel types had no effect. Open KV channels 
maintain resting potentials meaning no vasoconstriction or vasodilation, but further 
activation of KV channels leads to hyperpolarisation resulting in vasodilation 
(Rainbow et al, 2006). KV channel inhibition leads to depolarisation, resulting in 
vasoconstriction (Rainbow et al, 2006). 
Some studies show that the activities of KV channels can be affected by high levels 
of glucose (Liu et al, 2001; Kinoshita et al, 2004). This may be due to the formation 
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of superoxide in response to elevated levels of glucose (Rainbow et al, 2006; Liu et 
al, 2001; Li et al, 2004). Superoxide can then interact with endogenous NO to form 
peroxynitrite, which can inhibit both KV and BKCa channels, causing vasoconstriction 
(Rainbow et al, 2006; Li et al, 2004). In addition, inhibition of various K channels by 
high glucose levels appears to be dependent on protein kinase C (PKC) activation 
(Rainbow et al, 2006). It is unclear as to how elevated levels of glucose may affect 
vasodilation by HNO, or whether HNO interacts with superoxide or peroxynitrite. 
Reactive nitrogen species may also cause posttranslational modifications to channel 
proteins by s-nitrosylation of cysteine residues (Gonzalez et al, 2009).  
With evidence that KV channels are inhibited with high levels of glucose (Rainbow et 
al, 2006; Liu et al, 2001; Li et al, 2004), this study could provide further evidence of 
the involvement of KV channels in HNO mediated vasodilation. It is expected that 
there will be reduced levels of vasodilation with elevated glucose.  
It is important to know of the mechanisms elicited by increased levels of glucose, as 
it can have major importance in disease states, for example, in type 1 diabetes 
mellitus. It is clear that elevated glucose levels can cause vascular dysfunction, by 
inhibition of potassium channels, which can cause hypertension (Liu et al, 2001; Li et 
al, 2004), particularly in diabetic patients (Chukwuma, 1992; Williams, 1995; Way et 
al, 2001). This may be due to hyperglycaemia causing an increase in the PKC 
pathway (Rainbow et al, 2006; Way et al, 2001). Hypertension in diabetics is one of 
the main causes of complications including cardiovascular disease (Williams, 1995) 
and diabetic nephropathy (Chukwuma, 1992). Hyperglycaemia can also inhibit the 
actions of various vasodilators that act on potassium channels, for example, CGRP 
(Quayle et al, 1994; Aiello et al, 1995; Wellman et al, 1998).  
Methods 
Tissue Collection 
This study uses aortic ring preparations from male Wistar rats. Animals used were 
killed using the approved schedule 1 methods of killing; cervical dislocation and 
decapitation, carried out by trained staff (Animals in Scientific Procedures Act, 1986). 
There were no procedures carried out prior to schedule 1 killing, and the animals 
were checked daily to maintain good welfare. There was no lasting harm, pain or 
distress to the animals. At the present time there is no alternative to using animal 
models to study vascular smooth muscle function. The numbers of animals required 
was kept to a minimum by the use of a single rat for up to 7 different studies per day, 
and up to 4 aorta preparations can be taken from 1 animal.  
For this study the descending aorta was dissected from the Wistar rat, and was 
transferred to a dish containing Tyrode’s solution. Then the surplus connecting tissue 
was stripped from the outside of the aorta, and the aorta was cut into sections of 
around 5mm long. The sections were only handled using forceps at the edges of the 
sections to avoid damaging the endothelium as far as possible. The sections of aorta 
were then mounted horizontally across two hooks as in figure 1.  
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Mounting in Organ Bath 
The lower hook was attached to the bottom of the reservoir, and the top hook was 
attached to cotton thread and connected to a calibrated isometric transducer. The 
transducer was connected to LabChart and was calibrated using a 1g weight. The 
difference between nothing attached to the transducer, and the level when the 1g 
weight was added was then set to 1g in the LabChart software.  
The organ bath was kept in a water bath at a constant temperature of 38°C, and was 
filled with Tyrode’s solution. The Tyrode’s solution was aerated using carbogen gas 
to pH balance the solution.  
Solutions 
The physiological solution used for these experiments is Tyrode’s solution. This is 
made up of NaCl 140mM, Glucose 5.55mM, sodium bicarbonate 11.9mM, KCl 
2.68mM, NaH2PO4 0.4mM, CaCl2 1.84 mM and MgCl2 1.4mM. A high glucose 
version of Tyrode’s solution was also used with the same components, but with a 
glucose level of 27.75mM. The drug used to constrict the aorta was phenylephrine, 
with a provided stock solution of 100mM, which was diluted in Tyrode’s solution to 
make a stock of 1mM. The preliminary experiments used sodium nitroprusside 
(SNP) to relax the aorta. This was also provided in a 100mM stock solution, and was 
diluted in Tyrode’s solution to produce stocks of 10μM, 100μM, 1mM and 10mM. The 
main experiments used Angeli’s salt to relax the aorta, also at a given stock of 
100mM. This was then diluted in 1mM NaOH to generate stocks of 10μM, 100μM, 
1mM and 10mM. These stocks were then stored on ice to prevent self dimerisation 
of HNO (Fukuto & Carrington, 2011). During the main experiments, 
hydroxocobalamin (HxC) was used at 100μM, and L-Cysteine was used at 3mM. 
SNP Dose Response 
The mounted aorta section was typically mounted at a tension of around 2g, and left 
to equilibrate in the organ bath for around 15 minutes. A preliminary experiment was 
then carried out using 1 and 3μM phenylephrine to establish maximum constriction, 
and SNP, an NO donor, at increasing concentrations from 10nM to 30μM, to 
establish maximal relaxation. This produced a trace in LabChart of tension changes 
measured by the transducer, showing the response of the aortic section to 
increasing concentrations of SNP. The changes in tension following each addition of 
Figure 1: Diagram showing the setup for the mounting of 
the aortic ring preparations 
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SNP were calculated and tabulated and the percentage of maximal relaxation was 
determined. These percentages were then displayed graphically.  
Dose Response with Angeli’s Salt 
For these experiments, it was established that only 1μM phenylephrine was needed 
to cause maximum constriction of the aorta. The initial dose response curve was 
generated adding increasing concentrations of Angeli’s salt from 10nM to 30μM, and 
monitoring relaxation. Following this, dose response curves were generated in the 
presence of HxC, which is an NO scavenger, ensuring all results are due to HNO 
and not oxidation of HNO to NO or endogenously produced NO. In addition, a 
negative control was included, using L-Cysteine, which is an HNO scavenger and 
HxC, which should show whether there are any other acting mechanisms. These 
curves were then generated in a high glucose environment. The reservoir was 
washed out with Tyrode’s buffer in between experiments, and then was filled with 
fresh buffer, to prevent contamination of results. The values for tension changes 
were then tabulated, and graphs produced to compare the results. 
Statistical Analysis 
Each trace produced had to be analysed to compare and contrast results. The 
average tension achieved following each addition of drugs was taken from each 
trace and tabulated. The differences between each addition of relaxant and the 
maximum constriction achieved with phenlyephrine were then calculated. The largest 
difference achieved with SNP was deemed to be the maximal relaxation, therefore 
was 100% relaxation. Using this, percentage of total relaxation was then calculated 
for all difference values. The mean of the percentages obtained from the same 
conditions was then calculated, and then the standard deviation was calculated. 
These data were then presented graphically with the standard deviation presented 
as error bars, in order to compare the effect of glucose on vasodilation.  
Results 
Response of aorta to SNP 
The preliminary experiments show the expected rapid relaxation with increasing 
concentrations of SNP (Figure 2 & 3). Figure 2 shows a typical trace produced by 
adding 1μM and 3μM phenylephrine followed by increasing concentrations of SNP. 
Figure 3 was constructed by finding the differences in tension following each addition 
of SNP from the maximum point following phenylephrine addition. These were then 
converted to percentages using the largest difference as the maximal relaxation 
therefore 100%. This maximal relaxation value using SNP was then used as the 
100% value for comparison of the Angeli’s salt dose response curves.  
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Response of aorta to Angeli’s Salt 
Figure 4 shows a typical LabChart trace produced under normal glucose conditions 
with constriction by 1μM phenylephrine, addition of the NO scavenger HxC, and 
relaxation by increasing concentrations of Angeli’s salt. The shape of the curve at 
higher concentrations of Angeli’s salt is due to the breakdown of the HNO in solution, 
stopping it from causing relaxation to the smooth muscle. Figures 5 & 6 were 
constructed using traces like these, by measuring the differences in tension from the 
maximum constriction point and each addition of Angeli’s salt, just before the 
addition of the next increase in concentration. These differences were then 
converted into percentages of maximum relaxation, using the maximum with SNP as 
the 100% value, and then these percentages were plotted against Angeli’s salt 
concentration.  
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Figure 3: Graph showing the rapid relaxation with increasing concentrations 
of SNP. 
Figure 2: Typical trace produced by LabChart, showing constriction with 
phenylephrine and relaxation with increasing concentrations of SNP. 
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There was only about 50% of total relaxation achieved with a concentration of 3μM 
of Angeli’s salt (Figure 5 & 6), and then the aorta constricted slightly, so with the 
highest concentration of Angeli’s salt (30μM), there was around 45% of total 
relaxation. When the NO scavenger, HxC was added, the relaxation also achieved 
around 45% of maximum, but there was no relaxation, and slight constriction, at the 
lower concentrations (<1μM) of Angeli’s salt (Figure 5). Between 3-30μM additions, 
the relaxation was very rapid. The standard deviation was very low for the lower 
concentrations of Angeli’s salt, indicating minimal error, but the standard deviation 
was very high for the higher concentrations of Angeli’s salt, meaning high variability 
in the results.  
The curve with Angeli’s salt and HxC in a high glucose environment did not produce 
any relaxation until 3μM and then there was a small amount of relaxation up to 
30μM. However the highest amount of relaxation achieved was less than 10%. The 
standard deviation was relatively low across these results, indicating low variability in 
the results (Figure 5). 
The negative control used the HNO scavenger L-Cysteine in addition to Angeli’s salt 
and HxC. This curve shows a gradual relaxation throughout additions of Angeli’s salt, 
with a maximum relaxation achieved of around 25%. The standard deviation was low 
for these results, which indicates low variability (Figure 6). There appears to be more 
relaxation with L-Cysteine in normal glucose conditions than without L-Cysteine in 
high glucose conditions. The result for relaxation by Angeli’s salt in the presence of 
HxC and L-Cysteine in high glucose conditions shows constriction until 3μM of 
Angeli’s salt is accumulated, and eventually achieves around 25% of total relaxation 
(Figure 6). Both results in high glucose conditions show less relaxation than their 
counterparts in normal glucose conditions, and both curves generated in the 
presence of L-Cysteine show more relaxation than without L-Cysteine under normal 
glucose conditions (Figure 5 & 6). 
 
Figure 4: Typical trace produced by LabChart, showing constriction with 
phenylephrine and relaxation with increasing concentrations of Angeli’s salt, in 
the presence of HxC and under normal glucose conditions. 
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Figure 6: Graph showing mean relaxation with increasing concentrations of Angeli’s salt 
with HxC and L-Cysteine present, with and without high glucose levels. The error bars 
represent the standard deviation. 
 
Figure 5: Graph showing mean relaxation with increasing concentrations of Angeli’s salt 
with HxC present, with and without high glucose levels. The error bars represent the 
standard deviation. 
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Discussion 
This study overall shows that high levels of glucose will reduce the ability of the aorta 
to relax. This indicates the involvement of KV channels, as these channels are 
inhibited by high levels of glucose (Liu et al, 2001; Kinoshita et al, 2004).  This was, 
generally, the expected result, as KV channels have been implicated in the relaxation 
of smooth muscle in response to HNO (Yuill et al, 2011). The results obtained in this 
study are solely due to HNO as there was HxC used, which scavenges NO.  
However, both curves generated in the presence of L-Cysteine show more relaxation 
than the curve without L-Cysteine in the presence of high glucose. In reality, there 
should be no relaxation with L-Cysteine and HxC present together, as they will 
scavenge HNO and NO respectively. This result could be due to the L-Cysteine that 
was used could be non functional, or there could be another endothelium dependent 
relaxation mechanism in play.  
There was a large amount of variability in some of the results, particularly at higher 
concentrations of Angeli’s salt under normal glucose conditions with HxC. It is not 
clear exactly what caused this inconsistency, but there are occasionally errors in 
preparation of the physiological buffer, in particular, with reduced calcium levels 
there will be reduced contractility of the smooth muscle. In addition, the carbogen 
gas can be variable in the pressure and volume that is used to aerate the buffer.  
The shape of the curve generated in figure 5 changed when HxC was added. This is 
most likely due to the actions of NO at lower concentrations of Angeli’s salt addition 
without the addition of HxC. These actions are eliminated by the scavenging actions 
of HxC. This result appears to agree with a 2001 study by Ellis et al, where the 
actions of HNO were found to be due to oxidation to NO, via the use of the NO 
scavengers, HxC and carboxy-PTIO in the aorta. This study speculated that this may 
be due to the oxidative environment of the aorta facilitating the oxidation of HNO to 
NO. 
Not all values from all traces gathered were analysed for percentage graphs. This 
was because on some occasions there was no reaction from the aorta when either 
phenylephrine, SNP or Angeli’s salt were added. These data were excluded as it 
would introduce more variability and error into the results, and would have no 
beneficial effect to either prove or disprove the hypothesis. 
This is a relatively simple study that is easy to replicate, and can be very adaptable. 
Minimal damage was made to the endothelium as all sections of aorta were carefully 
handled. In the statistical analysis, the difference between the tension when the 
constriction agent, phenylephrine, was added, and the tensions when each 
concentration of Angeli’s salt was added were taken, and were converted to 
percentages of maximum relaxation. This then cancels out the variability in the 
baseline tension, before any agent was added. There was also consistency kept in 
the experimental procedures, as the organ bath reservoir was kept in a temperature 
controlled water bath at 38°C, and the same volume of physiological buffer was used 
within the reservoir each time. The reservoir was washed out after each experiment 
to prevent the drugs used from impacting on the next test.  
Some of the main drawbacks of this type of study include that it cannot show how 
HNO will work in vivo, as there will be trauma to the tissues when dissected, and it is 
conducted under very controlled conditions that won’t be present in vivo. This study 
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will also not provide specific information as to the mechanism of how HNO is working 
and how glucose specifically interacts with channels or receptors in situations with 
high levels of glucose. This means the exact mechanisms of action can only be 
speculated at this point. The main method by which it can be proven that KV 
channels are involved is via patch clamp experiments, which will show changes in 
current, and have been used in a number of studies (Li et al, 2004; Yuill et al, 2011). 
Another drawback of this study is that the increased glucose concentration may have 
changed the osmolarity of the buffer, which can affect how the drugs perform. 
The findings of this study appear to agree with those of previous studies. This study 
has found that it is likely that KV channels are involved in HNO mediated 
vasodilation, as the relaxation is inhibited by glucose, and it has been shown that 
high levels of glucose affect the actions of KV channels (Rainbow et al, 2006). 
Previous studies that have used different methods to those in this study have shown 
that sGC is produced when HNO is administered, and activates KV channels to 
mediate an HNO concentration dependant relaxation (Irvine et al, 2003; Favarolo & 
Kemp-Harper, 2009; Yuill et al, 2011). 
Further research is needed to establish the exact interactions between HNO and 
glucose, in particular, whether glucose can affect HNO directly or whether there are 
other interactions at play. It could also prove useful to compare the effect of elevated 
levels of glucose on HNO and NO, as it is known how glucose inhibition of KV 
channels occurs with NO (by the inhibitory effects of peroxynitrite generated by 
reaction of superoxide with NO) (Rainbow et al, 2006; Li et al, 2004), but the 
mechanisms surrounding HNO are unknown. The methods in this study could also 
be built upon by testing at a range of environmental glucose concentrations, and 
possibly testing with no glucose. Testing various glucose levels may be able to 
provide useful information that could be pertinent to diabetic patients, as 
hyperglycaemia can lead to hypertension, which underlies many of the complications 
of diabetes (Chukwuma, 1992; Williams, 1995; Way et al, 2001). It could prove 
useful to know how severe the hyperglycaemia has to be to cause inhibition of 
vasorelaxation, hypertension, and ultimately complications arising from this. It may 
also be useful to test with ODQ to inhibit sGC to find out whether the mechanisms by 
which glucose inhibits potassium channels are sGC dependent or independent, as it 
has been shown that under normal glucose conditions, HNO activates sGC to cause 
activation of KV channels (Irvine et al, 2003). In addition, specific channel blockers 
could be used to pinpoint the exact channels involved in vasorelaxation in response 
to HNO, and involved in inhibition of relaxation by glucose. Glucose levels may also 
me important in terms of cardioprotection from ischemic injury. It has been shown 
that HNO can increase the activity of ATP dependant potassium (KATP) channels 
conferring cardioprotection (Queliconi et al, 2011), however, increased levels of 
glucose may cause a down regulation of the Kir6.2 component of the KATP channel 
(Moritz et al, 2001), which would affect cardioprotection by HNO.  
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